Skip to content
value.today

TORL Biotherapeutics LLC

Total raised
$158 M
1 round on record
Latest round
$158 M
Apr 2024
First round on record
Apr 2024
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of TORL Biotherapeutics LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2024$158 MNo. 1$50 to $250 million

TORL Biotherapeutics LLC: Raise no. 1, Apr 2024

Investors in this round

52 investors had bought by the notice of Apr 17, 2024: 52 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$158 M of $158 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • David Licata · Executive Officer, Director
  • Mark Alles · Executive Officer, Director
  • Amit Sinha · Director
  • Dennis Slamon · Director
  • Lynn Seely · Director
  • Mark Attanasio · Director
  • Neil O'Brien · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Licata, President. Newest notice filed Apr 17, 2024. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • TORL Biotherapeutics LLC chose not to state its revenue in its newest notice of a funding round (Apr 2024).

    SEC Form D · Apr 2024

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Apr 2024

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of TORL Biotherapeutics LLC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by TORL Biotherapeutics LLC
NameRoleNamed in
David LicataExecutive officerApr 2024
Mark AllesExecutive officerApr 2024
Amit SinhaDirectorApr 2024
David LicataDirectorApr 2024
Dennis SlamonDirectorApr 2024
Lynn SeelyDirectorApr 2024
Mark AllesDirectorApr 2024
Mark AttanasioDirectorApr 2024
Neil O'BrienDirectorApr 2024